Slone Partners Places Jeffrey Kasten as Chief Business Officer at Vertero Therapeutics

Experienced executive will focus on driving business development, strategic partnerships, corporate and portfolio strategy, and commercialization planning

Slone Partners, a national executive search firm specializing in life sciences and healthcare, announced the appointment of Jeffrey S. Kasten as Chief Business Officer at Vertero Therapeutics, a clinical-stage biotechnology company advancing treatments for neurodegenerative diseases.

Health Technology Insights: Adtalem Completes $150Million Buyback, Approves $750Million Program

In this role, Kasten will lead business development, strategic partnerships, corporate and portfolio strategy, and commercialization planning, supporting the growth of Vertero’s pipeline, including its lead Parkinson’s disease program, VT-5006, currently in Phase 1 clinical trials. Kasten brings over 20 years of experience in life sciences, with expertise in corporate and portfolio strategy and business development across top biopharmaceutical companies. He spent the last eight years at Sage Therapeutics as Vice President of Corporate and Portfolio Strategy and Business Development, where he guided enterprise strategy, optimized portfolio decisions, and advanced key external growth initiatives. Prior to Sage, he held senior commercial and strategic marketing roles at Biogen for 11 years and earlier worked at Putnam Associates and Bain & Company in consulting and management positions.

Health Technology Insights: Chai Discovery Announces $130 Million Series B To Transform Molecular Discovery

Sona Stroud, Senior Vice President and Partner at Slone Partners, said that Kasten brings a broad and seasoned perspective in business development and strategy that will be critical as Vertero expands its neurodegenerative disease portfolio. Stewart Campbell, Ph.D., CEO of Vertero, added that Kasten’s experience in partnership cultivation and pipeline growth, along with his strategic insight, will strengthen the company’s focus on developing therapies that improve patient outcomes and enhance the lives of those affected by neurodegenerative disorders.

Health Technology Insights: Algia Pharma Advances Non-Opioid Pain Treatment to Phase 2

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com

Source- businesswire

Tags: AI in healthcare, health tech, healthcare, healthcare technology, patient care, Technology

HealthTech Media Room

HealthTech Media Room is a leading B2B media publication platform providing in-depth coverage of the rapidly evolving healthcare technology and academic research sectors. Specializing in key focus areas such as MedTech, Pharma, Digital Health, Health IT, and Biotech, HealthTech Media Room delivers the latest news, trends, and insights across the entire HealthTech landscape. From breakthrough medical devices and innovative pharmaceuticals to cutting-edge digital health solutions, the platform highlights key players, strategic partnerships, and transformative technologies shaping the future of healthcare. Serving as a trusted resource for industry professionals, thought leaders, and healthcare organizations, HealthTech Media Room is dedicated to driving conversations and knowledge sharing in the global HealthTech community.